A research team has outlined how synthetic biology can accelerate discoveries in plant–microbe interactions, offering ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage ...

The researchers discovered that the lipid phosphatidylinositol-4-phosphate (PI4P)—usually scarce in the ER—acts as a ...

Some cells, such as immune cells, are highly mobile—they constantly remodel their shape, migrate toward a wound that needs to ...

Nabla Bio partners with Takeda to use its AI platform JAM for designing antibodies, receiving upfront payments and potential ...

Immatics is advancing Anzu-cel, a T-cell receptor therapy for melanoma with potential for significant annual revenue. Learn ...

The Research Collaboratory for Structural Bioinformatics Protein Data Bank, a global scientific resource based at Rutgers ...

The melanoma market is expected to witness sustained growth driven by continuous therapeutic innovation and wider patient access. Advances in immunotherapies and targeted treatments, along with ...

The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that President and Chief Executive Officer, Hyung Heon Kim,  will ...

DOR/ISL data presented show minimal changes in weight and body composition and no clinically meaningful effect on fasting lipids and the homeostatic model assessment of insulin resistance (HOMA-IR) ...

Neuronal membranes are much more than structural barriers: they are living interfaces—dynamic platforms enabling signaling, ion transport, energy ...